{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:58:07Z","timestamp":1788044287740,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ekir.2021.08.020","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T16:03:03Z","timestamp":1629734583000},"page":"2830-2839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients"],"prefix":"10.1016","volume":"6","author":[{"given":"Fumihiko","family":"Koiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7717-8945","authenticated-orcid":false,"given":"Shinji","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-2339","authenticated-orcid":false,"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-9201","authenticated-orcid":false,"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2021.08.020_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.08.020_bib2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10157-011-0502-5","article-title":"Diseases of the parathyroid gland in chronic kidney disease","volume":"15","author":"Komaba","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2021.08.020_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.08.020_bib4","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.08.020_bib5","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1359\/jbmr.080610","article-title":"Bone markers predict cardiovascular events in chronic kidney disease","volume":"23","author":"Fahrleitner-Pammer","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ekir.2021.08.020_bib6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2021.08.020_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2018.08.046","article-title":"CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies","volume":"278","author":"Reiss","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ekir.2021.08.020_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"Fukagawa","year":"2013","journal-title":"Ther Aphre Dial"},{"key":"10.1016\/j.ekir.2021.08.020_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/ckj\/sfx125","article-title":"Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes","volume":"11","author":"Pereira","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2021.08.020_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1471-2369-14-100","article-title":"Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends","volume":"14","author":"Lafrance","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2021.08.020_bib11","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2215\/CJN.04350420","article-title":"Trends in mineral metabolism treatment strategies in patients receiving hemodialysis in the United States","volume":"15","author":"Hall","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.08.020_bib12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.08.020_bib13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40261-018-0687-4","article-title":"Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: first-in-human phase I study","volume":"38","author":"Akizawa","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ekir.2021.08.020_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204896","article-title":"Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: a randomized, double-blind, placebo-controlled, dose-finding study","volume":"13","author":"Akizawa","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2021.08.020_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195316","article-title":"A\u00a0novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in\u00a0vivo and in\u00a0vitro","volume":"13","author":"Kawata","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2021.08.020_bib16","first-page":"101","article-title":"Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan","volume":"10","author":"Shigematsu","year":"2018","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.ekir.2021.08.020_bib17","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"Fukagawa","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2021.08.020_bib18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/1744-9987.13434","article-title":"Evocalcet, a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism","volume":"24","author":"Akizawa","year":"2019","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.ekir.2021.08.020_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s10157-018-1635-6","article-title":"Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients","volume":"23","author":"Shigematsu","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2021.08.020_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10157-019-01692-y","article-title":"Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients","volume":"23","author":"Tsuruya","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2021.08.020_bib21","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1093\/ndt\/14.10.2398","article-title":"The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism","volume":"14","author":"Malberti","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.08.020_bib22","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1038\/s41598-019-42017-z","article-title":"Long-term efficacy and safety of evocalcet in Japanese patients with secondary hyperparathyroidism receiving hemodialysis","volume":"9","author":"Yokoyama","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2021.08.020_bib23","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2215\/CJN.02110310","article-title":"Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism","volume":"5","author":"Komaba","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2021.08.020_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1359\/jbmr.2001.16.4.605","article-title":"Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function","volume":"16","author":"Gao","year":"2001","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ekir.2021.08.020_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1530\/eje.0.1460407","article-title":"Effects of acute and chronic hypercalcemia on parathyroid function and circulating parathyroid hormone molecular forms","volume":"146","author":"D\u2019Amour","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ekir.2021.08.020_bib26","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1210\/jc.2005-0243","article-title":"Direct in\u00a0vitro evidence of extracellular Ca2+-induced amino-terminal truncation of human parathyroid hormone (1-84) by human parathyroid cells","volume":"90","author":"Kawata","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2021.08.020_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1210\/er.2003-0024","article-title":"Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands","volume":"26","author":"Murray","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ekir.2021.08.020_bib28","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ndt\/gfh038","article-title":"Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism","volume":"19","author":"Kazama","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2021.08.020_bib29","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s10157-014-1045-3","article-title":"Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy","volume":"19","author":"Koda","year":"2015","journal-title":"Clin Exp Nephrol"}],"updated-by":[{"DOI":"10.1016\/j.ekir.2021.09.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000}}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024921014054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024921014054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T20:54:20Z","timestamp":1636145660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024921014054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2468024921014054"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2021.08.020","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ekir.2021.09.011","asserted-by":"object"}]},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2021.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}